Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Macarena de la Fuente"'
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Glioblastoma Multiforme (GBM) is the most common malignant primary brain tumor. Despite aggressive multimodality treatment it remains one of the most challenging and intractable cancers (1]. While current standard of care treatment for GBM is maximal
Externí odkaz:
https://doaj.org/article/59735820d6ca442eb1da83427d26f1ca
Autor:
Priscilla K. Brastianos, Erin L. Twohy, Elizabeth R. Gerstner, Timothy J. Kaufmann, A. John Iafrate, Jochen Lennerz, Suriya Jeyapalan, David E. Piccioni, Varun Monga, Camilo E. Fadul, David Schiff, Jennie W. Taylor, Sajeel A. Chowdhary, Chetan Bettegowda, George Ansstas, Macarena De La Fuente, Mark D. Anderson, Nicole Shonka, Denise Damek, Jose Carrillo, Lara J. Kunschner-Ronan, Rekha Chaudhary, Kurt A. Jaeckle, Francis M. Senecal, Thomas Kaley, Tara Morrison, Alissa A. Thomas, Mary R. Welch, Fabio Iwamoto, David Cachia, Adam L. Cohen, Shivangi Vora, Michael Knopp, Ian F. Dunn, Priya Kumthekar, Jann Sarkaria, Susan Geyer, Xiomara W. Carrero, Maria Martinez-Lage, Daniel P. Cahill, Paul D. Brown, Caterina Giannini, Sandro Santagata, Frederick G. Barker, Evanthia Galanis
Publikováno v:
Journal of Clinical Oncology. 41:618-628
PURPOSE Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with NF2 loss. Given the predominance of NF2 mutations in meningiomas, we eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13d92dd4797c6a215de625e0d33d141d
https://doi.org/10.1200/jco.21.02371
https://doi.org/10.1200/jco.21.02371
Autor:
Priscilla K, Brastianos, Erin L, Twohy, Elizabeth R, Gerstner, Timothy J, Kaufmann, A John, Iafrate, Jochen, Lennerz, Suriya, Jeyapalan, David E, Piccioni, Varun, Monga, Camilo E, Fadul, David, Schiff, Jennie W, Taylor, Sajeel A, Chowdhary, Chetan, Bettegowda, George, Ansstas, Macarena, De La Fuente, Mark D, Anderson, Nicole, Shonka, Denise, Damek, Jose, Carrillo, Lara J, Kunschner-Ronan, Rekha, Chaudhary, Kurt A, Jaeckle, Francis M, Senecal, Thomas, Kaley, Tara, Morrison, Alissa A, Thomas, Mary R, Welch, Fabio, Iwamoto, David, Cachia, Adam L, Cohen, Shivangi, Vora, Michael, Knopp, Ian F, Dunn, Priya, Kumthekar, Jann, Sarkaria, Susan, Geyer, Xiomara W, Carrero, Maria, Martinez-Lage, Daniel P, Cahill, Paul D, Brown, Caterina, Giannini, Sandro, Santagata, Frederick G, Barker, Evanthia, Galanis
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship withEligible patients whose tumors screened positively forOf 322 patients screened fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::15320c49eedc56725b5f7b9cc65c4517
https://pubmed.ncbi.nlm.nih.gov/36288512
https://pubmed.ncbi.nlm.nih.gov/36288512
Autor:
Vaidya Govindarajan, Ashish H. Shah, Long Di, Sarah Rivas, Robert K. Suter, Daniel G. Eichberg, Evan Luther, Victor Lu, Alexis A. Morell, Michael E. Ivan, Ricardo J. Komotar, Nagi Ayad, Macarena De La Fuente
Publikováno v:
World Neurosurg
BACKGROUND: Isocitrate dehydrogenase (IDH) mutations are present in 70% of World Health Organization grade II and III gliomas. IDH mutation induces accumulation of the oncometabolite 2-hydroxyglutarate. Therefore, therapies targeting reversal of epig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e34252addc395e2364af3636352299
https://europepmc.org/articles/PMC9177782/
https://europepmc.org/articles/PMC9177782/
Autor:
Yash S, Soni, Benjamin J, Rich, Deukwoo, Kwon, Wei, Zhao, Danny L, John, Crystal, Seldon, Jessica, Meshman, Ronald, Benveniste, Ricardo J, Komotar, Macarena, de la Fuente, Maria Del Pilar, Guillermo Prieto, Gregory, Azzam, Eric A, Mellon, Carolina G, Benjamin, Tejan, Diwanji
Publikováno v:
J Radiosurg SBRT
OBJECTIVES: Patients undergoing stereotactic radiosurgery (SRS) for brain metastases require additional radiation for relapse. Our objective is to determine the factors associated with salvage SRS versus whole brain radiation therapy (WBRT) for salva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7ee00403251705a833833748c728a71b
https://pubmed.ncbi.nlm.nih.gov/36275132
https://pubmed.ncbi.nlm.nih.gov/36275132
Autor:
Ashish H Shah, Robert Suter, Pavan Gudoor, Tara T Doucet-O’Hare, Vasileios Stathias, Iahn Cajigas, Macarena de la Fuente, Vaidya Govindarajan, Alexis A Morell, Daniel G Eichberg, Evan Luther, Victor M Lu, John Heiss, Ricardo J Komotar, Michael E Ivan, Stephan Schurer, Mark R Gilbert, Nagi G Ayad
Publikováno v:
Neurooncol Adv
Background Poor prognosis of glioblastoma patients and the extensive heterogeneity of glioblastoma at both the molecular and cellular level necessitates developing novel individualized treatment modalities via genomics-driven approaches. Methods This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3692abc106e4ff4cc7ca87a06ee6669f
https://doi.org/10.1093/noajnl/vdab192
https://doi.org/10.1093/noajnl/vdab192
Autor:
Corinne E Griguer, Claudia R Oliva, Christopher S Coffey, Merit E Cudkowicz, Robin A Conwit, Anna L Gudjonsdottir, Dixie J Ecklund, Janel K Fedler, Tina M Neill-Hudson, Louis B Nabors, Melanie Benge, James R Hackney, Marianne Chase, Timothy P Leonard, Toral Patel, Howard Colman, Macarena de la Fuente, Rekha Chaudhary, Karen Marder, Teri Kreisl, Nimish Mohile, Milan G Chheda, Katharine McNeill, Priya Kumthekar, Aclan Dogan, Jan Drappatz, Vinay Puduvalli, Agnes Kowalska, Jerome Graber, Elizabeth Gerstner, Stephen Clark, Michael Salacz, James Markert
Publikováno v:
Neuro-oncology Advances
Background Glioblastoma (GBM) has a 5-year survival rate of 3%-5%. GBM treatment includes maximal resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ). Cytochrome C oxidase (CcO) is a mitochondrial enzyme involved in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee80388673e3937853bea9f5e5b3a0db
http://europepmc.org/articles/PMC8788017
http://europepmc.org/articles/PMC8788017
Autor:
Robert Suter, Anna Jermakowicz, Vasileios Stathias, Luz Ruiz, Matthew D'Antuono, Simon Kaeppeli, Grace Baker, Rithvik Veeramachaneni, Winston Walters, Maria Cepero, Sion Williams, Michael Ivan, Ricardo Komotar, Macarena De La Fuente, Jann Sarkaria, Stephan Schürer, Nagi Ayad
Publikováno v:
Neuro-Oncology. 24:vii118-vii118
Glioblastoma (GBM) remains the most common and lethal adult primary brain cancer. Two of the most significant issues preventing the development of effective GBM treatments are inter- and intra-tumor heterogeneity. To address these issues, we develope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a42ad84687371a96f4b30eb55db0a62e
https://doi.org/10.1093/neuonc/noac209.449
https://doi.org/10.1093/neuonc/noac209.449
Autor:
Ugonma Chukwueke, Elizabeth Vera, Alvina Acquaye, Shawn Hervey-Jumper, Yazmin Odia, Laura Klesse, Erin Dunbar, Akanksha Sharma, Ekokobe Fonkem, Alissa Thomas, Tamra Werbowetski-Ogilvie, Sandra Camelo-Piragua, Na Tosha Gatson, Macarena de la Fuente, Terri Armstrong, Alyx Porter, Sadhana Jackson
Publikováno v:
Neuro-Oncology. 23:vi151-vi151
BACKGROUND Neuro-oncology has grown tremendously since 2010, marked by increasing society membership, specialized clinical expertise, and new journals. Yet, modest improvement in racial/ethnic diversity amongst clinical trial participants, researcher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f9fae7dc1950ce5d2af2a0fef36d141
https://doi.org/10.1093/neuonc/noab196.593
https://doi.org/10.1093/neuonc/noab196.593
Autor:
David Reardon, Seema Nagpal, Scott Soltys, Steven Brem, Antonio Omuro, Macarena De La Fuente, Amy-Lee Bredlau, Isreal Lowy, Matthew Fury, Matthew Morrow, Kim Kraynyak, Trevor McMullan, Ashley L. Santo, Brian Sacchetta, Jeffrey Skolnik
Publikováno v:
Cancer Research. 79:CT114-CT114
Despite advances in therapy, glioblastoma (GBM) remains one of the most deadly cancers, with five-year survival under 5%. Newer immunotherapies hold promise in the treatment of GBM, and T cell-enabling therapies may improve progression-free and overa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1e1561277eb4654afb077ee4ef5120e
https://doi.org/10.1158/1538-7445.am2019-ct114
https://doi.org/10.1158/1538-7445.am2019-ct114